Literature DB >> 15388580

Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.

James T B Crawley1, Jonathan K Lam, James B Rance, Luigina R Mollica, James S O'Donnell, David A Lane.   

Abstract

The multimeric size and the function of circulating von Willebrand factor are modulated via its proteolytic cleavage by the plasma metalloproteinase, ADAMTS13. It is unclear how ADAMTS13 activity is regulated within the vascular system. In the absence of a regulatory mechanism, ADAMTS13 activity might compromise platelet adhesion at sites of vascular injury. We hypothesized that at sites of vascular injury, ADAMTS13 activity could be regulated locally by coagulation proteinases. Initiation of coagulation in human plasma resulted in the disappearance of added full-length recombinant ADAMTS13. This loss was inhibited by hirudin. Using purified proteins, we showed that ADAMTS13 is proteolyzed at several cleavage sites by thrombin in a time- and concentration-dependent manner. Furthermore, this proteolysis ablated ADAMTS13 activity against purified von Willebrand factor. Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited the proteolysis of ADAMTS13, suggesting the involvement of thrombin exosite I (and not exosite II) in ADAMTS13 recognition. Plasmin also cleaved ADAMTS13 into similar fragments, resulting in the loss of ADAMTS13 activity. This study demonstrates the susceptibility of ADAMTS13 to proteolytic inactivation and suggests possible roles for thrombin and plasmin at sites of vascular injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388580     DOI: 10.1182/blood-2004-03-1101

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  63 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  ADAMTS13 and 15 are not regulated by the full length and N-terminal domain forms of TIMP-1, -2, -3 and -4.

Authors:  Cenqi Guo; Anastasia Tsigkou; Meng Huee Lee
Journal:  Biomed Rep       Date:  2015-10-30

3.  [Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].

Authors:  T Schmidt; D A Tsakiris; M Grapow; M Siegemund
Journal:  Anaesthesist       Date:  2010-12-25       Impact factor: 1.041

Review 4.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 5.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

6.  Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.

Authors:  Sandra Lopez-Castaneda; Ignacio Valencia-Hernández; Carlos Arean; Daniel Godínez-Hernández; Martha Eva Viveros-Sandoval
Journal:  Clin Appl Thromb Hemost       Date:  2017-06-15       Impact factor: 2.389

7.  Thrombin-dependent MMP-2 activity is regulated by heparan sulfate.

Authors:  Bon-Hun Koo; Jung Ho Han; Young Il Yeom; Doo-Sik Kim
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

8.  Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Circ Res       Date:  2008-05-23       Impact factor: 17.367

9.  Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.

Authors:  Yoshiaki Chinen; Junya Kuroda; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Miki Kiyota; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Yosuke Matsumoto; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2013-03-14       Impact factor: 2.490

Review 10.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.